Your session is about to expire
← Back to Search
Antihistamine
Alcaftadine for Hay Fever ((OAT-PIT) Trial)
Phase 4
Waitlist Available
Led By Jayesh Kanuga, MD
Research Sponsored by Starx Research Center, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
(OAT-PIT) Trial Summary
To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.
Eligible Conditions
- Hay Fever
- Allergic Eye
(OAT-PIT) Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Quality of Life- Eye Allergy Patient Impact Questionnaire
Secondary outcome measures
Ocular Surface Disease Index Pollen Count correlation of symptoms
(OAT-PIT) Trial Design
1Treatment groups
Experimental Treatment
Group I: AlcaftadineExperimental Treatment1 Intervention
subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
Find a Location
Who is running the clinical trial?
Starx Research Center, LLCLead Sponsor
Jayesh Kanuga, MDPrincipal InvestigatorStarx Research Center, LLC
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger